|
25B-NBOMe (NBOMe-2C-B, Cimbi-36, Nova, BOM 2-CB) is a derivative of the phenethylamine psychedelic 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5HT2A receptor.〔Maria Silva PhD. (Theoretical study of the interaction of agonists with the 5-HT2A receptor. ) Universität Regensburg, 2009.〕 Anecdotal reports from users suggest 25B-NBOMe to be an active hallucinogen at a dose of as little as 250–500 µg, making it a similar potency to other phenethylamine derived hallucinogens such as bromo-dragonfly. Duration of effects lasts about 12–16 hours. The carbon-11 labeled version of this compound (()Cimbi-36) was synthesized and validated as a radioactive tracer for positron emission tomography (PET) in Copenhagen.〔Hansen, M. (2011). (Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain. ) PhD Thesis, University of Copenhagen.〕〔 〕 As a 5-HT2A receptor agonist PET radioligand, ()Cimbi-36 was hypothesized to provide a more functional marker of these receptors. Also, ()Cimbi-36 is investigated as a potential marker of serotonin release and thus could serve as an indicator of serotonin levels in vivo. ()Cimbi-36 is now undergoing clinical trials as a PET-ligand in humans. == Toxicity and harm potential == One case has been reported on where 25B-NBOMe was identified as the cause of death for a 17-year-old boy. 25B-NBOMe has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram; Such a dose is 300× lower than the dose expected to be hallucinogenic to humans and it is expected that recreational use would greatly exceed doses determined to be safe to humans. Several deaths have been attributed to its close analogue 25I-NBOMe. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「25B-NBOMe」の詳細全文を読む スポンサード リンク
|